New detalimogene bladder cancer data send the minnow’s stock up 47%.
ApexOnco Front Page
Recent articles
The response rate jumps to 30% with higher doses of IMA402.
Nearly two thirds of key oncology filings are expedited; and what about the ones that aren’t?
Work targeting mesothelin, and some other antigens that have hitherto disappointed, continues.
The group has approval for Amtagvi, but now faces the prospect of a solo launch.
Approval on the basis of Flaura2 is part of a double success for Astra's Tagrisso, which has also scored in Laura.
GSK’s Zejula win is the latest chapter in a long and convoluted history of PARP inhibition.
Lifileucel heads up the list of upcoming US FDA catalysts.